Expert panelists review the management of non-clear cell histology in renal cell carcinoma, exploring treatment options, clinical trials, and the potential role of immune checkpoint inhibitors.
Applying ASCO GU 2024 Data to Clinical Practice in Bladder, RCC Care
FDA Approval Insights: Nadofaragene Firadenovec in BCG-Unresponsive NMIBC
Toripalimab Plus Axitinib Approved in China for Frontline Renal Cell Carcinoma
Blum Highlights Implications of CA-125 Levels in Renal Medullary Carcinoma
SABR Leads to Local Control in Primary RCC Without Surgery
NICE Endorses Cabozantinib Plus Nivolumab in Advanced RCC
Navigating the Intersection of Radiation Therapy and Immunotherapy in Endometrial Cancer
As Orthopedic Oncology Evolves, Caring for the Clinician Must Be a Priority
Belumosudil Produces Long-Term Responses Without New Safety Concerns in cGVHD
Prophylactic Itacitinib May Safely Mitigate CRS Following Axi-Cel Administration in Lymphoma